More evidence points to the benefits of germline genetic testing for patients with various cancers. Such testing can identify mutations that may warrant a change of treatment and allow trying a ...

Komen(R), the world's leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) for introducing legislation that would ...

Please provide your email address to receive an email when new articles are posted on . Nearly all individuals who self-navigated the entire online platform completed germline testing. The platform ...

From 7% to nearly 9% of patients with advanced cancer were found to harbor a germline variant with targeted therapeutic actionability in the first study of its kind. The study involved 11,974 patients ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

During the Miami Breast Cancer Conference and Educated Patient® Breast Cancer Summit, one expert stressed the importance of genetic testing for BRCA mutations. All patients who receive a diagnosis of ...

An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with breast cancer. Germline testing, or genetic testing of the DNA that a person ...

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...

Quality of care (QoC) measures among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment: A SEER-Medicare analysis.

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...

Multigene NGS on tumor tissue accurately identifies pathogenic variants in EOC, supporting a tumor-first genetic testing model. The study found 94.3% of tumors had detectable variants, with 99.1% ...